Researchers from Philadelphia-based Jefferson Health used an immunotherapy called Car-T cell therapy, which effectively eliminated metastatic CRC in mice.
Car-T immunotherapy involves removing a patient’s immune cells and reengineering them to target only the tumor. They then multiple the cells enmass and inject them back into the patient.
The cells specifically react to a tumor antigen called GUCY2C. The antigen is a potential biomarker and therapeutic agent.
In the study, researchers tested a human-ready version of the therapy on mice. All the mice survived with no side effects during the 75-day observation period.
They replicated the study in mice with CRC with lung metastases and discovered the therapy was equally successful. The mice survived more than 100 days with no metastases.
More articles on gastroenterology:
Task force releases intraocular surgical instrument sterilization guidelines for ASCs — 5 key insights
Demand more: What GI physicians should expect from their pathology lab
The payment shift: patients as payers
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
